JP4818585B2 - 細胞系の産生および維持に関連する物質および方法 - Google Patents

細胞系の産生および維持に関連する物質および方法 Download PDF

Info

Publication number
JP4818585B2
JP4818585B2 JP2003552950A JP2003552950A JP4818585B2 JP 4818585 B2 JP4818585 B2 JP 4818585B2 JP 2003552950 A JP2003552950 A JP 2003552950A JP 2003552950 A JP2003552950 A JP 2003552950A JP 4818585 B2 JP4818585 B2 JP 4818585B2
Authority
JP
Japan
Prior art keywords
cells
cell
stat5
protein
stat5b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003552950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512540A6 (ja
JP2005512540A (ja
Inventor
ハーゲン・スピッツ
マリアンヌ・ナスペッティ
フェレンク・スケーレン
ビアンカ・ブロム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130223A external-priority patent/GB0130223D0/en
Priority claimed from GB0206086A external-priority patent/GB0206086D0/en
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2005512540A publication Critical patent/JP2005512540A/ja
Publication of JP2005512540A6 publication Critical patent/JP2005512540A6/ja
Application granted granted Critical
Publication of JP4818585B2 publication Critical patent/JP4818585B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
JP2003552950A 2001-12-18 2002-12-18 細胞系の産生および維持に関連する物質および方法 Expired - Lifetime JP4818585B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0130223A GB0130223D0 (en) 2001-12-18 2001-12-18 Materials and methods relating to the production and maintenance of cell lines
GB0130223.1 2001-12-18
GB0206086.1 2002-03-14
GB0206086A GB0206086D0 (en) 2002-03-14 2002-03-14 Materials and methods relating to the production and maintenance of cell lines
PCT/GB2002/005753 WO2003052083A2 (fr) 2001-12-18 2002-12-18 Materiaux et procedes associes a la production et a l'entretien de lignees cellulaires

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009048001A Division JP2009142292A (ja) 2001-12-18 2009-03-02 細胞系の産生および維持に関連する物質および方法

Publications (3)

Publication Number Publication Date
JP2005512540A JP2005512540A (ja) 2005-05-12
JP2005512540A6 JP2005512540A6 (ja) 2005-08-04
JP4818585B2 true JP4818585B2 (ja) 2011-11-16

Family

ID=26246880

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003552950A Expired - Lifetime JP4818585B2 (ja) 2001-12-18 2002-12-18 細胞系の産生および維持に関連する物質および方法
JP2009048001A Pending JP2009142292A (ja) 2001-12-18 2009-03-02 細胞系の産生および維持に関連する物質および方法
JP2012198276A Pending JP2012235795A (ja) 2001-12-18 2012-09-10 細胞系の産生および維持に関連する物質および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009048001A Pending JP2009142292A (ja) 2001-12-18 2009-03-02 細胞系の産生および維持に関連する物質および方法
JP2012198276A Pending JP2012235795A (ja) 2001-12-18 2012-09-10 細胞系の産生および維持に関連する物質および方法

Country Status (10)

Country Link
US (2) US8318487B2 (fr)
EP (2) EP2141228A1 (fr)
JP (3) JP4818585B2 (fr)
AT (1) ATE555194T1 (fr)
AU (1) AU2002352436B2 (fr)
DK (1) DK1458855T3 (fr)
ES (1) ES2384960T3 (fr)
NZ (1) NZ534107A (fr)
SI (1) SI1458855T1 (fr)
WO (1) WO2003052083A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560916A1 (fr) * 2002-11-08 2005-08-10 ReproCELL Inc. Agents d'expansion pour cellules souches
ATE474915T1 (de) 2003-11-19 2010-08-15 Us Gov Health & Human Serv Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen
EP1627563A1 (fr) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Moyens et méthodes de préparation de cellules stabilisées
JP2008509663A (ja) * 2004-08-10 2008-04-03 アカデミシュ メディシュ セントラム ビ デ ユニベルシテイト ファン アムステルダム 関心のある安定化された細胞を生産するための手段及び方法
ATE512228T1 (de) 2005-11-17 2011-06-15 Tet Systems Gmbh & Co Kg Induzierbare expressionssysteme
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
PL2540820T3 (pl) 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
EP1997830A1 (fr) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
WO2010053987A2 (fr) * 2008-11-04 2010-05-14 Duke University Production d'anticorps monoclonaux dans des lymphocytes b et leurs utilisations
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP6013356B2 (ja) 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
WO2015115892A1 (fr) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Moyens et procédés de production d'anticorps stables
JP6684211B2 (ja) 2014-07-02 2020-04-22 学校法人東京理科大学 Ｂ細胞集団の製造方法
EP4341283A2 (fr) * 2021-05-14 2024-03-27 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Protéines de fusion inductibles par activité ayant un facteur de transcription et un domaine de liaison à la protéine de choc thermique 90

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044774A2 (fr) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme
WO2000061602A1 (fr) * 1999-04-08 2000-10-19 Isis Pharmaceuticals, Inc. Modulation de l'expression des stat3, au moyen d'oligonucleotides antisens
WO2002097050A2 (fr) * 2001-05-31 2002-12-05 Novartis Ag Nouveaux variants du domaine de liaison aux ligands du recepteur oestrogenique et nouveaux ligands et compositions pharmaceutiques
WO2003032898A2 (fr) * 2001-07-23 2003-04-24 Immunex Corporation Lymphopoietine thymique stromale (tslp) humaine modifiee

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665221B2 (en) 1991-12-02 1995-12-21 Cambridge Antibody Technology Limited Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2188165C (fr) * 1994-04-28 2007-08-28 Marilyn Kehry Methode de multiplication et differenciation des cellules b et leur utilisation
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US20020090692A1 (en) * 1999-09-30 2002-07-11 Prayaga Sudhirdas K. Novel polynucleotides and polypeptides encoded thereby

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044774A2 (fr) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme
WO2000061602A1 (fr) * 1999-04-08 2000-10-19 Isis Pharmaceuticals, Inc. Modulation de l'expression des stat3, au moyen d'oligonucleotides antisens
WO2002097050A2 (fr) * 2001-05-31 2002-12-05 Novartis Ag Nouveaux variants du domaine de liaison aux ligands du recepteur oestrogenique et nouveaux ligands et compositions pharmaceutiques
WO2003032898A2 (fr) * 2001-07-23 2003-04-24 Immunex Corporation Lymphopoietine thymique stromale (tslp) humaine modifiee

Also Published As

Publication number Publication date
JP2012235795A (ja) 2012-12-06
DK1458855T3 (da) 2012-07-23
US20090275139A1 (en) 2009-11-05
EP1458855A2 (fr) 2004-09-22
JP2005512540A (ja) 2005-05-12
WO2003052083A3 (fr) 2003-11-27
US8318487B2 (en) 2012-11-27
AU2002352436A1 (en) 2003-06-30
AU2002352436B2 (en) 2008-05-22
US20060153820A1 (en) 2006-07-13
EP1458855B1 (fr) 2012-04-25
US8389281B2 (en) 2013-03-05
SI1458855T1 (sl) 2012-08-31
ES2384960T3 (es) 2012-07-16
WO2003052083A2 (fr) 2003-06-26
EP2141228A1 (fr) 2010-01-06
ATE555194T1 (de) 2012-05-15
JP2009142292A (ja) 2009-07-02
NZ534107A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
JP2012235795A (ja) 細胞系の産生および維持に関連する物質および方法
US10273454B2 (en) Means and methods for influencing the stability of antibody producing cells
Scheeren et al. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression
JP2005512540A6 (ja) 細胞系の産生および維持に関連する物質および方法
US20070289029A1 (en) Means and Methods for Producing a Stabilized Cell of Interest
JP4435563B2 (ja) アポトーシスプロセスの阻害および細胞性能の改善
ZA200404859B (en) Methods for the generation of proliferating and differentiating cell lines
Patel Role of the MHC class II transactivator in CD4 T cell differentiation
Ström Regulation of the murine immunoglobulin GL gamma-1 and epsilon promoters

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110608

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110802

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110831

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140909

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4818585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term